Markets:

Overview

News

Currencies

International

Treasuries

Jazz Pharmaceuticals plc - Ordinary Shares (NQ:JAZZ)

189.74 +2.89 (+1.55%)

Streaming Delayed Price Updated: 2:59 PM EDT, Apr 7, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Jazz Pharmaceuticals plc - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9

...

16 17 Next >

2 Incredible Growth Stocks That Are Screaming Buys for 2024 ↗

January 22, 2024

These healthcare businesses are compelling buys for very different reasons.

Via The Motley Fool

4 Remarkable Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip ↗

January 13, 2024

The growth-fueled Nasdaq Composite remains 7% below its all-time high, which means bargains can still be found.

Via The Motley Fool

Topics Stocks

US Stocks Set To Open Weaker As Traders Eye Key Main Street Events: Analyst Sees Buying Opportunity On 'Stunning' Earnings Expectations ↗

January 03, 2024

Several market-moving catalysts, including the release of the Fed minutes, a Federal Reserve speech, and JOLTS data, could influence the day's market movement.

Via Benzinga

Topics Economy

Decoding 6 Analyst Evaluations For Jazz Pharmaceuticals ↗

January 03, 2024

Via Benzinga

7 Growth Stocks Poised to Thrive in a Post-Fed Pivot World ↗

December 28, 2023

If the Federal Reserve loosens the monetary spigot, these companies could represent the growth stocks to buy now.

Via InvestorPlace

Topics Economy

Analyst Ratings for Jazz Pharmaceuticals ↗

November 29, 2023

Via Benzinga

Jazz Pharmaceuticals: Q3 Earnings Insights ↗

November 08, 2023

Via Benzinga

Jazz Pharmaceuticals' Post-Traumatic Stress Disorder Drug Disappoints In Mid-Stage Study ↗

December 22, 2023

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) announced top-line results from the Phase 2 trial of JZP150, an investigational small molecule selective fatty acid amide hydrolase (FAAH) inhibitor, on efficacy...

Via Benzinga

3 No-Brainer Stocks to Buy With $500 Right Now ↗

December 20, 2023

You don't need a mountain of cash to build wealth on Wall Street.

Via The Motley Fool

Japan Approves Marijuana-Derived Medicines, Adopt 7-Year Prison Sentences For Recreational Use ↗

December 06, 2023

Japan’s Parliament passed a bill Wednesday legalizing medical products derived from cannabis.

Via Benzinga

Australian MPs Admit They Tried Cannabis, Signaling Policy Reform & Epidiolex For Seizures Approved In Canada ↗

November 30, 2023

Around 8% of Australians are using medical marijuana either occasionally or regularly, according to a recent survey of 1,000 participants conducted by consumer insights company Antenna, reported...

Via Benzinga

Topics Cannabis

3 Top-Rated Biotech Stocks That Analysts Are Loving Now ↗

November 28, 2023

Investing in biotech stocks can be tricky, but analysts have bullish outlooks on these three, promising companies.

Via InvestorPlace

Pot Stocks: Values Or Traps? ↗

November 22, 2023

Pot stocks were the hottest thing around five years ago but after catching a bid during the pandemic, the stocks have now plunged to multi-year lows.

Via Talk Markets

Topics Cannabis

3 Biotech Stocks That Could Be Millionaire Makers ↗

November 22, 2023

Many biotech stocks offer exciting long-term growth prospects.

Via The Motley Fool

Police Boss Turned Cannabis Reform Advocate, MMJ Legalization In Japan And More Global Updates ↗

November 16, 2023

Medical Cannabis-Based Epidiolex Advances Through Japan's Legislature Earlier this week, Japanese policymakers gave the green light to a measure to legalize medical products derived from cannabis,...

Via Benzinga

Topics Cannabis

3 No-Brainer Stocks to Buy With $200 Right Now ↗

November 15, 2023

A modest amount of money can go a long way when it's invested in inexpensive, game-changing businesses.

Via The Motley Fool

Autifony Announces Exclusive Global License and Collaboration Agreement with Jazz Pharmaceuticals on Two Ion Channel Targets for Neurological Disorders

November 14, 2023

From Autifony Therapeutics Ltd

Via Business Wire

7 Healthcare Stocks That Are Poised to Become the Next Unicorns ↗

November 09, 2023

Discover healthcare stocks with remarkable potential for growth and "unicorn" status in the ever-evolving world of healthcare investments.

Via InvestorPlace

Cannabis Cash Burn Concerns? Sell These 7 Overbought Stocks Now. ↗

November 07, 2023

These overbought cannabis stocks are teetring on the edge as the sector is navigating through uncharted waters.

Via InvestorPlace

Topics Cannabis

FDA Report On Its 50 Years In Cannabis Research, Signals A Boost In Medical Marijuana Prospects ↗

November 03, 2023

Researchers with the Food and Drug Administration (FDA) reported Wednesday on the agency’s 50 years of experience with marijuana research. In an article titled “FDA’s 50

Via Benzinga

Topics Cannabis

Ireland Reimburses Medical Marijuana-Based Drug For Chemotherapy-Induced Nausea And Vomiting ↗

October 30, 2023

Althea Group Holdings Limited (ASX: AGH), an Australian manufacturer of cannabis-based medicines and recreational cannabis products confirmed that Ireland’s Primary Care Reimbursement...

Via Benzinga

Topics Cannabis

Global Cancer Vaccines Market Share Is Expected To Reach $19.27 Billion By 2030

October 25, 2023

EQNX::TICKER_START (OTCPK:DTCFF),(CSE:DTC),(NASDAQ:JAZZ),(NASDAQ:EXEL),(NASDAQ:AMGN),(NASDAQ:REGN) EQNX::TICKER_END

Via FinancialNewsMedia

Europe's High: UK Parents Need NHS Help For Daughter's Seizures, THC MMJ Flowers In Switzerland & More ↗

October 24, 2023

Luxembourg: Medical Marijuana Shortage Due To Supplier Change

Via Benzinga

Topics Cannabis Supply Chain

Cannabis Stocks Dip: How Rising Interest Rates Impact Your Portfolio ↗

October 23, 2023

On Friday, cannabis stocks traded lower with the overall market. Marketfy analyst Michael Berger will be monitoring how the sector performs this week.

Via Benzinga

Topics Cannabis

Europe's High: Irish GPs Against Pot, Switzerland-Spain Share Data On Cannabis Clubs & More ↗

October 20, 2023

Denmark: Medical Marijuana Pilot Program Experience 90% Growth In 12 Months

Via Benzinga

Topics Cannabis

Jazz Pharmaceuticals Explores Asset Sale Option, Possibly Cannabinoid Business: Report ↗

October 20, 2023

Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) is reportedly exploring strategic options comprising a potential sale.

Via Benzinga

2 Top Biotech Stocks to Buy in October ↗

October 03, 2023

Growth catalysts lie ahead for both of these players.

Via The Motley Fool

5 Genius Safe Stocks to Buy for the 4th Quarter of 2023 ↗

October 02, 2023

These highly profitable, time-tested companies can deliver for their shareholders in any economic climate.

Via The Motley Fool

4 Perfect Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip ↗

September 30, 2023

An 18% decline in the Nasdaq Composite from its all-time high means bargains still abound.

Via The Motley Fool

Topics Stocks

Benzinga's Top Ratings Upgrades, Downgrades For September 29, 2023 ↗

September 29, 2023

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

16 17 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Jazz Pharmaceuticals plc - Ordinary Shares (NQ:JAZZ)

All News about Jazz Pharmaceuticals plc - Ordinary Shares

Starting at $3.75/week.

Subscribe Today